Atara Biotherapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 earnings with an EPS of $-0.56, missing estimates by -17.0% against an expected $-0.48. Revenue increased by $4.03 million year-over-year. The company's past earnings performance shows a pattern of missing EPS estimates, which previously led to a 6.0% drop in share price the following day.
March 28, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics reported a Q4 EPS of $-0.56, missing estimates by -17.0%, with a revenue increase of $4.03M YoY. Historical data shows past misses have negatively impacted share price.
Given Atara Biotherapeutics' history of missing EPS estimates and the subsequent negative impact on its share price, as evidenced by a 6.0% drop following last quarter's earnings miss, it's likely that this quarter's miss could similarly lead to a short-term decrease in share price. The -17.0% miss on EPS estimates is significant, and the historical pattern suggests investors react negatively to such news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100